tetano
Editor, Senior Moderator
Cell Rep Med
. 2021 Apr 5;100252.
doi: 10.1016/j.xcrm.2021.100252. Online ahead of print.
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
Marco Mandolesi[SUP] 1 [/SUP], Daniel J Sheward[SUP] 1 2 [/SUP], Leo Hanke[SUP] 1 [/SUP], Junjie Ma[SUP] 1 [/SUP], Pradeepa Pushparaj[SUP] 1 [/SUP], Laura Perez Vidakovics[SUP] 1 [/SUP], Changil Kim[SUP] 1 [/SUP], Monika Adori[SUP] 1 [/SUP], Klara Lenart[SUP] 3 [/SUP], Karin Lor?[SUP] 3 [/SUP], Xaquin Castro Dopico[SUP] 1 [/SUP], Jonathan M Coquet[SUP] 1 [/SUP], Gerald M McInerney[SUP] 1 [/SUP], Gunilla B Karlsson Hedestam[SUP] 1 [/SUP], Ben Murrell[SUP] 1 [/SUP]
Affiliations
Abstract
The outbreak and spread of SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), is a current global health emergency, and effective prophylactic vaccines are needed urgently. The spike glycoprotein of SARS-CoV-2 mediates entry into host cells, and thus is the target of neutralizing antibodies. Here, we show that adjuvanted protein immunization with soluble SARS-CoV-2 spike trimers, stabilized in prefusion conformation1, results in potent antibody responses in mice and rhesus macaques, with neutralizing antibody titers exceeding those typically measured in SARS-CoV-2 seropositive humans by more than one order of magnitude. Neutralizing antibody responses were observed after a single dose, with exceptionally high titers achieved after boosting. A follow-up to monitor waning of the neutralizing antibody responses in rhesus macaques demonstrated durable responses that were maintained at high and stable levels at least 4 months after boosting. Taken together, these data support the development of adjuvanted SARS-CoV-2 prefusion-stabilized spike protein subunit vaccines.
. 2021 Apr 5;100252.
doi: 10.1016/j.xcrm.2021.100252. Online ahead of print.
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
Marco Mandolesi[SUP] 1 [/SUP], Daniel J Sheward[SUP] 1 2 [/SUP], Leo Hanke[SUP] 1 [/SUP], Junjie Ma[SUP] 1 [/SUP], Pradeepa Pushparaj[SUP] 1 [/SUP], Laura Perez Vidakovics[SUP] 1 [/SUP], Changil Kim[SUP] 1 [/SUP], Monika Adori[SUP] 1 [/SUP], Klara Lenart[SUP] 3 [/SUP], Karin Lor?[SUP] 3 [/SUP], Xaquin Castro Dopico[SUP] 1 [/SUP], Jonathan M Coquet[SUP] 1 [/SUP], Gerald M McInerney[SUP] 1 [/SUP], Gunilla B Karlsson Hedestam[SUP] 1 [/SUP], Ben Murrell[SUP] 1 [/SUP]
Affiliations
- PMID: 33842900
- PMCID: PMC8020888
- DOI: 10.1016/j.xcrm.2021.100252
Abstract
The outbreak and spread of SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2), is a current global health emergency, and effective prophylactic vaccines are needed urgently. The spike glycoprotein of SARS-CoV-2 mediates entry into host cells, and thus is the target of neutralizing antibodies. Here, we show that adjuvanted protein immunization with soluble SARS-CoV-2 spike trimers, stabilized in prefusion conformation1, results in potent antibody responses in mice and rhesus macaques, with neutralizing antibody titers exceeding those typically measured in SARS-CoV-2 seropositive humans by more than one order of magnitude. Neutralizing antibody responses were observed after a single dose, with exceptionally high titers achieved after boosting. A follow-up to monitor waning of the neutralizing antibody responses in rhesus macaques demonstrated durable responses that were maintained at high and stable levels at least 4 months after boosting. Taken together, these data support the development of adjuvanted SARS-CoV-2 prefusion-stabilized spike protein subunit vaccines.